Xybion announces a major biotechnology company licenses
Pristima for early discovery pathology data management
(1888PressRelease) Xybion Corporation announced that its Pristima Preclinical
Software suite has been selected as the primary preclinical platform for early-stage
drug discovery pathology data management by a Top-5 global biotech firm.
(1888PressRelease) CEDAR KNOLLS, NJ: Xybion Corporation announced that its
Pristima Preclinical Software suite has been selected as the primary preclinical
platform for early-stage drug discovery pathology data management by a Top-5 global
biotech firm. The new Xybion client becomes the third major biotech laboratory in the
Cambridge Massachusetts Biotechnology Research hub to choose Pristima Suite as
the centerpiece for its drug discovery and early stage development efforts.
This leading biotech company has licensed Pristima Suite for use by all of its
pathologists. Xybion's professional services team will provide all installation and
training services to get the client in production. The client selected Pristima Suite as
the most efficient and user-friendly solution with a robust set of off-the-shelf reports
and an architecture designed to scale as the facility expands. Following a rigorous
evaluation process that included key stakeholders across the company's enterprise,
Pristima rose to the top of the vendor list for a variety of reasons.
Carlos Frade, Vice President Preclinical Solutions for Xybion commented on the new
client; "In addition to our biotechnology client sites on the west coast in California
and Washington, Xybion understands the importance of the research community in
the Cambridge, MA area and are pleased to see how Pristima Suite plays such a role
in the early discovery arena. For both early discovery safety assessment and for safety
pharmacology, Pristima provides the simple, easy-to-use data management toolsets
and features that cater to the dynamic approaches in early discovery".
The client will be leveraging many of the key features, modules and services that are
part of the Pristima Suite. Some of the key components to be used immediately are
the Integrated Protocol & Pathology modules along with a robust reporting framework
that includes detailed Study metrics and statistics that are vital to the pathologists.
The client will also be leveraging the rapid and efficient deployment services provided
by Xybion as part of its total preclinical solution.
Mr. Frade added, "Software alone cannot move the ball forward for early drug
discovery. Companies require more real-time visibility into their preclinical

---

operations. The Pristima Total Preclinical Solution adds value because it facilitates
the process of drug development from formulation through FDA submissions. Our
services and rapid deployment offering, which is part of the total preclinical solution
package, was a key differentiator for Xybion at this company and a big part of the
reason they had selected us".
Dr. Pradip Banerjee, CEO of Xybion stated; "We are extremely proud of this particular
contract award since it affirms our strategy to a Total Preclinical Solution. Our
relationship with this key client shows our global capabilities with respect to
interconnected preclinical data management and validates Xybion's ability to deliver
valuable solutions on a global scale to life science companies".
About Xybion Corporation: http://www.xybion.com
Xybion Corporation is a global leader in the development and delivery of critical
enterprise solutions to highly regulated industries, helping companies lower cost,
mitigate risk and accelerate growth, while managing quality and compliance. Xybion
is the maker of Pristima Suite, a leading preclinical data management solution for the
life science sector. Pristima Suite is the only fully integrated preclinical and vivarium
management solution that natively connects to enterprise quality & compliance
management processes on the market today.
Trackback Url :
http://www.1888pressrelease.com/preclinical-software/xybion/xybion-announces-a-
major-biotechnology-company-licenses-pris-pr-392194.html
###

---

Document Outline

• 

---